title: Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?
abstract: The widely used antiretroviral agent tenofovir disoproxil fumarate has been associated with proximal tubular injury and decreased glomerular filtration rate in HIV-infected individuals. Phase 3 trials of a new prodrug, tenofovir alafenamide, suggest a lower potential for kidney injury.
authors.affiliation: Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: christina.wyatt@mssm.edu.
authors.forename: Christina M
authors.initials: CM
authors.lastname: Wyatt
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000409:Alanine; D000998:Antiviral Agents / Q000009:adverse effects*; D017326:Clinical Trials, Phase III as Topic; D003404:Creatinine / Q000097:blood / Q000652:urine; D017277:Drug Approval; D004338:Drug Combinations; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007687:Kidney Tubules, Proximal / Q000187:drug effects*; D011355:Prodrugs / Q000009:adverse effects*; D000068698:Tenofovir / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D004338:Drug Combinations; D011355:Prodrugs; D000068698:Tenofovir; D003404:Creatinine; C442442:tenofovir alafenamide; D000225:Adenine; D000409:Alanine